Table 1.
Summary of published intravenous midazolam studies for data analysis.
| Study | n (M/F) |
Age (years) |
Weight (kg) |
Midazolam dose |
Inhibitor or inducer/activator |
Assay | Collection Timepoint (h) |
Reference |
|---|---|---|---|---|---|---|---|---|
| 1 | 14 (6/7) | 19–50 | 55–96 | 0.025 mg/kg | none | LC/MS/MS | 0, 0.083, 0.5, 1, 2, 4, 5, 6 | 17 |
| 2 | 11 (8/3) | 24–45 | 67–102 | 0.025 mg/kg | none | LC/MS/MS | 0, 0.083, 0.5, 1, 2, 4, 5, 6 | 21 |
| 3a | 14 (8/6) | 36.1a | 55–98 | 1 mg | none | HPLC-MS | 0, 0.083, 0.5, 1, 2, 4, 5, 6 | 18 |
| 3b | 1 mg | Pleconaril 400 mg 3 times daily × 16 doses | HPLC-MS | 0, 0.083, 0.5, 1, 2, 4, 5, 6 | 18 | |||
| 4a | 11 (3/8) | 20–36 | N/A | 2 mg | none | LC/MS/MS | 0, 0.03, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 | 19 |
| 4b | 12 (3/9) | Aprepitant 125 mg ×1 dose | LC/MS/MS | 0, 0.03, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 | 19 | |||
| 5a | 9 (6/3) | 19–41 | 54–87 | 2 mg | none | GC | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 | 4 |
| 5b | 2 mg | Ketoconazole 200 mg X3 doses | GC | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 | 4 | |||
| 6a | 19 (17/2) | 21–28 | 52–81 | 1 mg | none | LC-MS-MS | 0, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12 | 20 |
| 6b | Itraconazole 200 mg once daily × 4 days | LC-MS-MS | 0, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12 | 20 | ||||
| 6c | Rifampin 600 mg once daily × 10 days | LC-MS-MS | 0, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12 | 20 | ||||
| 7 | 16 (14/2) | 18–42 | 61–95 | 1mg | none | HPLC-MS | 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 1012, 24 | 22 |
a
Mean age
Abbreviations: GC, gas chromatography; HPLC, high performance liquid chromatography; LC, liquid chromatography; MS, mass spectrometry; N/A, not applicable.